Patents by Inventor Joshua Thomas PEARSON

Joshua Thomas PEARSON has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INTERLEUKIN-2 MUTEINS FOR THE EXPANSION OF T-REGULATORY CELLS
    Publication number: 20240327485
    Abstract: Provided herein are IL-2 muteins and IL-2 mutein Fc-fusion molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also, provided herein are linker peptides that are glycosylated when expressed in mammalian cells.
    Type: Application
    Filed: April 4, 2024
    Publication date: October 3, 2024
    Applicant: Amgen Inc.
    Inventors: Marc Alain GAVIN, Gunasekaran KANNAN, Li Li, Joshua Thomas PEARSON, Margaret KAROW
  • Interleukin-2 muteins for the expansion of T-regulatory cells
    Patent number: 11976102
    Abstract: Provided herein are IL-2 muteins and IL-2 mutein Fc-fusion molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also, provided herein are linker peptides that are glycosylated when expressed in mammalian cells.
    Type: Grant
    Filed: October 5, 2020
    Date of Patent: May 7, 2024
    Assignee: Amgen Inc.
    Inventors: Marc Alain Gavin, Gunasekaran Kannan, Li Li, Joshua Thomas Pearson, Margaret Karow
  • INTERLEUKIN-2 MUTEINS FOR THE EXPANSION OF T-REGULATORY CELLS
    Publication number: 20210094997
    Abstract: Provided herein are IL-2 muteins and IL-2 mutein Fc-fusion molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also, provided herein are linker peptides that are glycosylated when expressed in mammalian cells.
    Type: Application
    Filed: October 5, 2020
    Publication date: April 1, 2021
    Applicant: Amgen Inc.
    Inventors: Marc Alain GAVIN, Gunasekaran KANNAN, Li LI, Joshua Thomas PEARSON, Margaret KAROW